Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates real-time PET imaging of cspg4 in pancreatic and gastric carcinoma models, indicating improved monitoring capabilities.
Chondroitin sulfate proteoglycan 4 (CSPG4) is highly expressed in various solid tumors and promotes tumor progression and migration. Targeting CSPG4 therapy, such as monoclonal antibodies 9.2.27 and CAR-M, has already been in clinical trials. Database analysis further correlated elevated levels of CSPG4 with reduced overall survival in both cancers. Achieving real-time visualization of aberrant CSPG4 expression in various solid tumors remains a critical issue that needs to be addressed. To address this, we pioneered the preparation of three 68Ga-labeled PET probes targeting CSPG4, [68Ga]Ga-DOTA-LS10, [68Ga]Ga-DOTA-SH11, and [68Ga]Ga-DOTA-TH10. In pancreatic (ASPC1) and gastric (MKN45) carcinoma models, [68Ga]Ga-DOTA-TH10 showed prominent tumor uptake (ASPC1:1.63 ± 0.15%ID/g at 60 min), validated by Western blot and immunohistochemistry confirming CSPG4 overexpression. This study conducted the first PET imaging on CSPG4 expression in pancreatic cancer and gastric cancer models using 68Ga-labeled peptides, aiming to provide guidance for clinical real-time monitoring of its expression.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: